30 completed, 15 unknown, 14 recruiting, 8 active not recruiting. 49 Phase 2, 21 Phase 1, 12 Phase 3, 3 Early Phase 1, 3 Not applicable.
Follow folfirinox: new trials by email Literature Review of folfirinox trials Research Report on folfirinox
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of the Efficacy and Safety of Neoadjuvant Therapy in Patients With Surgically Resectable Pancreatic Adenocarcinoma. GnP, FOLFIRINOX - Pancreatic Adenocarcinoma Resectable, Non Metastatic | Phase 2 | Not yet recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 42 | 2027-01-01 | 2026-09-15 |
| Efficacy and Safety of Serplulimab in Combination With Bevacizumab and FOLFIRINOX or NALIRIFOX as Second-Line Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Serplulimab and Bevacizumab injection, FOLFIRINOX/NALIRIFOX, S-1 - Metastatic Pancreatic Ductal Adenocarcinoma | Phase 2 | Not yet recruiting | Shanghai General Hospital, China | 34 | 2026-08-01 | 2026-07-29 |
| Personalizing Chemotherapy Selection After Surgery for Patients With Stage III Colorectal Cancer Using a Blood Test Capecitabine, Oxaliplatin, Folfirinox - Colorectal Cancer | Phase 3 | Active not recruiting | UNICANCER | 2450 | 2026-07-20 | 2026-07-22 |
| Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal Liver Metastasis Doxorubicin, FOLFOX, Botensilimab, Balstilimab, Bevacizumab, FOLFIRI, FOLFIRINOX, AGEN2373 - Colorectal Cancer Metastatic | Early Phase 1 | Recruiting | Northwell Health | 10 | 2025-12-10 | 2026-06-24 |
| AG Followed by FOLFIRINOX Both Combined With PD-L1 Antibodies as a Conversion Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer. Treatment: AG & anti-PD-L1 + FOLFIRINOX & anti-PD-L1 - Pancreatic Cancer | Phase 2 | Not yet recruiting | Shanghai Zhongshan Hospital | 77 | 2025-10-10 | 2025-10-06 |
| Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial) FLOT, FOLFOX, FOLFIRI - Gastroesophageal Adenocarcinoma | Phase 1 | Recruiting | University of California, Irvine | 20 | 2025-06-27 | 2026-03-10 |
| Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel Gemcitabine, Nab paclitaxel, Erlotinib - Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer | Phase 1 / Phase 2 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 104 | 2025-02-06 | 2026-04-23 |
| Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5) Pembrolizumab, Folfirinox, SABR - Localized Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Amsterdam UMC, location VUmc | 66 | 2024-09-23 | 2026-02-13 |
| Evaluation of an Early Radiomic Signature in Patients With Metastatic Pancreatic Adenocarcinoma Treated With First-line Chemotherapy Patients treated with FOLFOX or FOLFIRINOX in first line, Patients treated with GEMCITABINE in first line - Pancreatic Cancer, MeSH Term-Pancreatic Cancer, Adult) | Active not recruiting | Assistance Publique - Hôpitaux de Paris | 400 | 2024-01-09 | 2025-11-21 | |
| Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR/LAPC FOLFIRINOX or gemcitabine-nab-paclitaxel - Locally Advanced Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Carcinoma | Phase 3 | Recruiting | Sahlgrenska University Hospital | 432 | 2023-10-18 | 2024-12-03 |
| The ADAPTA Study: ADjuvant chemotherAPy After Curative Intent resecTion of Ampullary Cancer. Folfirinox, Capox - Ampullary Adenocarcinoma | Recruiting | Fondazione Poliambulanza Istituto Ospedaliero | 400 | 2023-07-01 | 2023-10-05 | |
| NeoFOL-R Trial (Perioperative Versus Adjuvnat FOLFIRINOX in Resectable Pancreatic Cancer) Folfirinox - Resectable Pancreatic Cancer, Neoadjuvant Chemotherapy | Phase 3 | Recruiting | Seoul National University Hospital | 609 | 2023-04-01 | 2024-11-27 |
| Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer Biopsy, FOLFIRINOX, Ciprofloxacin - Pancreatic Cancer | Phase 2 | Recruiting | Icahn School of Medicine at Mount Sinai | 25 | 2023-03-16 | 2024-10-15 |
| Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study) Spevatamig (PT886), Paclitaxel, Gemcitabine - Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Phanes Therapeutics | 350 | 2023-03-15 | 2026-09-28 |
| A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors IBI343, FOLFIRINOX/mFOLFIRINOX, mFOLFOX - Locally Advanced Unresectable or Metastatic Solid Tumors | Phase 1 | Recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 470 | 2022-10-26 | 2026-05-04 |
| Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer Pembrolizumab, Folfirinox - Pancreatic Ductal Adenocarcinoma | Phase 2 | Recruiting | Baylor College of Medicine | 30 | 2022-08-31 | 2026-08-04 |
| FOLFIRINOX + NIS793 in Pancreatic Cancer FOLFIRINOX, Oxaliplatin, Leucovorin - Pancreas Cancer, Metastatic Pancreatic Cancer | Phase 1 | Terminated | Colin D. Weekes, M.D., PhD | 4 | 2022-08-09 | 2025-11-18 |
| Redefining FOLFIORINOX in Older Pancreatic Cancer Patients FOLFIRINOX - Metastatic Pancreatic Cancer | Phase 2 | Active not recruiting | Fox Chase Cancer Center | 37 | 2022-04-22 | 2026-10-29 |
| Survival Analysis After Neoadjuvant Therapy in Patients With Resectable Pancreatic Cancer and Risk Factors Folfirinox and Stereotactic Body Radiotherapy - Pancreatic Adenocarcinoma, Pancreatic Cancer Resectable | Phase 2 / Phase 3 | Unknown | Instituto de investigación e innovación biomédica de Cádiz | 116 | 2022-04-15 | 2022-08-09 |
| CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without Panitumumab CEND-1, Panitumumab, Folfirinox - Colon Cancer, Pancreas Cancer | Phase 1 / Phase 2 | Unknown | Anup Kasi | 50 | 2021-10-20 | 2024-12-17 |
Showing 20 of 82. Sign in to see all of them.
Pancreatic Neoplasms (45) · Colorectal Neoplasms (6) · Neoplasms (6) · Neoplasm Metastasis (4) · Adenocarcinoma (3) · Biliary Tract Neoplasms (2) · Carcinoma, Hepatocellular (2) · Rectal Neoplasms (2) · Carcinoma (1) · Carcinoma, Islet Cell (1) · Carcinoma, Pancreatic Ductal (1) · Cholangiocarcinoma (1) · Colonic Neoplasms (1) · Diabetes Mellitus, Insulin-Dependent, 12 (1) · Gastro-enteropancreatic neuroendocrine tumor (1)
Massachusetts General Hospital (5) · Institut du Cancer de Montpellier - Val d'Aurelle (4) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (3) · Sun Yat-sen University (3) · Indiana University (2) · Seoul National University Hospital (2) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2) · UNC Lineberger Comprehensive Cancer Center (2) · University Health Network, Toronto (2) · University of Louisville (2) · Ability Pharmaceuticals SL (1) · Abramson Cancer Center at Penn Medicine (1) · Amsterdam UMC, location VUmc (1) · Andrew Ko (1) · Anup Kasi (1)
United States (42) · France (12) · China (8) · South Korea (5) · Spain (5) · Canada (4) · Israel (4) · Netherlands (4) · Germany (3) · Italy (3) · Sweden (3) · Belgium (2) · Brazil (2) · Australia (1) · Austria (1)
Jennifer Y. Wo, MD (2) · Amina Mokrani, A/Prof (1) · Andrew Ko, M.D. (1) · Antoine Adenis, MD (1) · Anup Kasi, MD (1) · Ashwin Somasundaram, MD (1) · Autumn J McRee, MD (1) · Colin D Weekes, MD, PHD (1) · Daniel Laheru, M.D. (1) · Davendra Sohal, Sohal (1) · David Ryan, MD (1) · Deirdre Cohen, MD (1) · Derek L West, MD, MS (1)
PMID 41486497, PMID 19095497, PMID 20065174, PMID 20375404, PMID 21561347, PMID 23955585, PMID 25027973, PMID 26674592, PMID 27022826, PMID 27918777, PMID 29471013, PMID 29800971, PMID 30080723, PMID 30207593, PMID 30220234, PMID 30959462, PMID 31063184, PMID 31070690, PMID 31145418, PMID 31494181, PMID 31512497, PMID 31564556, PMID 31640628, PMID 31919404, PMID 32293352, PMID 32497895, PMID 32681477, PMID 33630475, PMID 33862000, PMID 33926539, PMID 34288696, PMID 35293148, PMID 37041522, PMID 37678921, PMID 37936126, PMID 38126766, PMID 38155512, PMID 38957079, PMID 38987363, PMID 39088774, PMID 39235326, PMID 40670773, PMID 40802908, PMID 41044171, PMID 41591505, PMID 41812337, PMID 41915391
2009 (1), 2023 (1)